An expert explains how the new program, which launches July 1, will work and who is eligible ...

More than 1 in 10 U.S. adults is currently taking a GLP-1 weight-loss drug. And these medicines are getting cheaper seemingly ...

Coverage of Lilly’s obesity medications is expanding in the near future. Here’s why that matters.

GLP-1 medications like Ozempic and Wegovy are used for weight loss and diabetes. Learn how they work, their costs, and potential side effects.

Carley is a writer, editor and social media professional. Before starting at Forbes Health, she wrote for Sleepopolis and interned at PBS and Nickelodeon. She's a certified sleep science coach and ...

Learn who qualifies for Medicare’s GLP-1 Bridge, when $50 Wegovy and Zepbound access begins, and key rules beneficiaries need to know before July 2026.

Big shifts GLP-1 market include FDA approval of oral weight loss drugs and expanded Medicare coverage starting July 2024 for key GLP-1 therapies.

Falling prescription drug costs are emerging as a key development in the broader push to rein in U.S. health care spending, with new pricing shifts beginning to show up at the pharmacy counter.

Diccon Hyatt is an experienced financial and economics reporter. He's written hundreds of articles breaking down complex financial topics in plain language, emphasizing the impact that economic ...

CMS Extends Medicare's Short-Term Bridge Program for GLP-1 Obesity Drug Coverage By Juliette Cubanski and KFF Health News HealthDay ReportersThe Centers for Medicare & Medicaid Services (CMS) has ...

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week ...

The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- from its 503B bulks list.